KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Capital Expenditures: 2018-2025

Historic Capital Expenditures for Castle Biosciences (CSTL) over the last 7 years, with Sep 2025 value amounting to $14.8 million.

  • Castle Biosciences' Capital Expenditures rose 132.58% to $14.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.4 million, marking a year-over-year increase of 48.27%. This contributed to the annual value of $28.3 million for FY2024, which is 107.96% up from last year.
  • Latest data reveals that Castle Biosciences reported Capital Expenditures of $14.8 million as of Q3 2025, which was up 60.14% from $9.3 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Capital Expenditures ranged from a high of $32.4 million in Q2 2021 and a low of -$29.7 million during Q4 2021.
  • For the 3-year period, Castle Biosciences' Capital Expenditures averaged around $6.4 million, with its median value being $5.2 million (2024).
  • Data for Castle Biosciences' Capital Expenditures shows a peak YoY increase of 1,747.04% (in 2021) and a maximum YoY decrease of 5,142.61% (in 2021) over the last 5 years.
  • Over the past 5 years, Castle Biosciences' Capital Expenditures (Quarterly) stood at -$29.7 million in 2021, then surged by 106.02% to $1.8 million in 2022, then surged by 112.26% to $3.8 million in 2023, then soared by 99.50% to $7.6 million in 2024, then surged by 132.58% to $14.8 million in 2025.
  • Its last three reported values are $14.8 million in Q3 2025, $9.3 million for Q2 2025, and $4.7 million during Q1 2025.